Cardio Diagnostics Holdings Inc

Price Chart

Risk-Adjusted Performance

Also Listed On

Cardio Diagnostics Holdings Inc (CDIO) Price Performance

Cardio Diagnostics Holdings Inc (CDIO) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $2.14, down 6.55% from the previous close.

Over the past year, CDIO has traded between a low of $1.05 and a high of $15.60. The stock has lost 83.3% over this period. It is currently 86.3% below its 52-week high.

Cardio Diagnostics Holdings Inc has a market capitalization of $5.11M.

About Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.